semaglutide obesity phase 3 once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, 3a trial Novo Nordisk makes headway in

It also shows how much interest there is in understanding where these substances fit within current pharmacy and regulatory frameworks

Ways to Reduce Irritation If your injection site reaction is causing you significant pain, rash, or itching, contact your healthcare provider

This suggests that it is intended for multiple uses over time, rather than as a one-time treatment

For example, if you were on a high dose of semaglutide, you might move to a lower dose once a week, or stay at the higher dose every 10 to 14 days

In March 2024, the FDA added a second indication: reducing the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease and obesity or overweight, making it the first weight loss drug to carry that designation